Murray B E
University of Texas Houston-Medical School, Houston 77030, USA.
Emerg Infect Dis. 1998 Jan-Mar;4(1):37-47. doi: 10.3201/eid0401.980106.
Enterococci are associated with both community- and hospital-acquired infections. Even though they do not cause severe systemic inflammatory responses, such as septic shock, enterococci present a therapeutic challenge because of their resistance to a vast array of antimicrobial drugs, including cell-wall active agents, all commercially available aminoglycosides, penicillin and ampicillin, and vancomycin. The combination of the latter two occurs disproportionately in strains resistant to many other antimicrobial drugs. The propensity of enterococci to acquire resistance may relate to their ability to participate in various forms of conjugation, which can result in the spread of genes as part of conjugative transposons, pheromone-responsive plasmids, or broad host-range plasmids. Enterococcal hardiness likely adds to resistance by facilitating survival in the environment (and thus enhancing potential spread from person to person) of a multidrug-resistant clone. The combination of these attributes within the genus Enterococcus suggests that these bacteria and their resistance to antimicrobial drugs will continue to pose a challenge.
肠球菌与社区获得性感染和医院获得性感染均有关联。尽管它们不会引发严重的全身炎症反应,如感染性休克,但由于肠球菌对大量抗菌药物具有耐药性,包括细胞壁活性剂、所有市售氨基糖苷类药物、青霉素、氨苄西林以及万古霉素,因此对其治疗构成了挑战。后两种药物的联合使用在对许多其他抗菌药物耐药的菌株中出现的比例过高。肠球菌获得耐药性的倾向可能与其参与各种形式接合作用的能力有关,这可能导致作为接合转座子、信息素响应质粒或广泛宿主范围质粒一部分的基因传播。肠球菌的顽强生命力可能通过促进多重耐药克隆在环境中的存活(从而增强人与人之间的潜在传播)而增加耐药性。肠球菌属内这些特性的结合表明,这些细菌及其对抗菌药物的耐药性将继续构成挑战。